| | |
| Summary |
| Please note: The McKinsey Quarterly has agreed to a special arrangement for CEOExpress members that allows member access to their articles. Articles must be clicked on directly through the links below to gain access to this group of articles.
|
Biopharma’s capacity crunch
The challenging part of biotechnology always seemed to be the creation of promising new biopharmaceuticals. Yet the industry may soon be losing revenues because of a more prosaic concern—insufficient manufacturing capacity to meet demand as new drugs come to market.
The take-away: Even at a cost of $250 million to $500 million for each of the industry's manufacturing plants, continued expansion is crucial. It won't come easily, however: the highly trained people needed to design, build, and operate them are also in short supply.
Articles provided by The McKinsey Quarterly
© 1992-2003 McKinsey & Company, Inc
|
|
|
